Kolon TissueGene made a hot comeback on the local stock market Tuesday, soaring to its maximum trading ceiling of 20,850 won ($14.5) just two minutes after the market’s opening.
A year and a half after the controversy over its gene therapy drug Invossa, Kolon TissueGene has been delisted from the domestic stock market.
Korea JoongAng Daily Sitemap